Nov 16 (Reuters) – Gilead Sciences said on Monday it had signed royalty-free deals with three generic drugmakers to make its experimental Ebola prevention drug available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals.
Here are more details:
• The deals with Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories cover obeldesivir, and include all African countries reporting cases in the current Ebola Bundibugyo outbreak
• Obeldesivir has shown activity against several Ebola-related viruses in preclinical studies but is not approved for any use in any country
• A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings
• Gilead is also expanding remdesivir licenses to cover Ebola-related diseases if trial results are positive and regulators approve the drug
• The company has donated more than 38,000 remdesivir vials to the Democratic Republic of Congo, Uganda and Kenya, including more than 2,000 recently sent to Kenya for investigational treatment and post-exposure prevention
• Remdesivir is not approved to treat or prevent Ebola Bundibugyo disease, and its clinical effectiveness has not been established
(Reporting by Kunal Das in Bengaluru; Editing by Tasim Zahid)

